{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:24:03Z","timestamp":1791239043933,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.diagmicrobio.2011.07.007","type":"journal-article","created":{"date-parts":[[2011,9,13]],"date-time":"2011-09-13T23:05:58Z","timestamp":1315955158000},"page":"252-259","source":"Crossref","is-referenced-by-count":61,"title":["Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method"],"prefix":"10.1016","volume":"71","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Diekema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn A.","family":"Messer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0005","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/AAC.44.6.1544-1548.2000","article-title":"Correlation of fluconazole MICs with clinical outcome in cryptococcal infection","volume":"44","author":"Aller","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0010","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1128\/AAC.01624-08","article-title":"Breakpoints for susceptibility testing should not divide wild-type distributions of important target species","volume":"53","author":"Arendrup","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0015","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/clinids\/23.6.1337-a","article-title":"Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis","volume":"23","author":"Armengou","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0020","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1086\/517056","article-title":"The hidden danger of primary fluconazole prophylaxis for patients with AIDS","volume":"26","author":"Berg","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0025","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/507895","article-title":"Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution","volume":"43","author":"Bicanic","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1086\/518607","article-title":"Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole","volume":"45","author":"Bicanic","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0035","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1473-3099(05)70197-3","article-title":"Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis","volume":"5","author":"Bicanic","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1439-0507.2006.01293.x","article-title":"Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya","volume":"50","author":"Bii","year":"2006","journal-title":"Mycoses"},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0045","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/095646249500600510","article-title":"Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis","volume":"6","author":"Birley","year":"1995","journal-title":"Int. J. STD AIDS"},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0050","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1128\/AAC.45.11.3065-3069.2001","article-title":"Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998","volume":"45","author":"Brandt","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0055","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1128\/AAC.37.6.1383","article-title":"Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole","volume":"37","author":"Casadevall","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0060","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s10096-004-1136-2","article-title":"In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia","volume":"23","author":"Chandenier","year":"2004","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0065","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.idc.2006.07.001","article-title":"Cryptococcosis","volume":"20","author":"Chayakulkeeree","year":"2006","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0070","series-title":"corresponding minimal inhibitory concentration (MIC) interpretive breakpoints and quality control limits for anitfungal disk diffusion susceptibility testing of yeasts: informational supplement (M44-S2)","article-title":"Zone diameter interpretive standards","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2007"},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0075","series-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts: third edition, M27-A3","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2008"},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0080","series-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts: 3rd informational supplement (M27-S3)","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2008"},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0085","series-title":"Method for antifungal disk diffusion susceptibility testing of yeasts: approved standard, M44-A2","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2008"},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0090","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1086\/339540","article-title":"Morbidity and mortality in South African gold miners: Impact of untreated disease due to human immunodeficiency virus","volume":"34","author":"Corbett","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0095","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/jac\/42.2.217","article-title":"In-vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole","volume":"42","author":"Davey","year":"1998","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0100","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00002030-200402200-00024","article-title":"Epidemiology of HIV-associated cryptococcosis in France (1985\u20132001): comparison of the pre- and post-HAART eras","volume":"18","author":"Dromer","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0105","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/clinids\/23.1.82","article-title":"Epidemiology of cryptococcosis in France: A 9-year survey (1985\u20131993). French Cryptococcosis Study Group","volume":"23","author":"Dromer","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0110","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1097\/00002030-200111230-00026","article-title":"Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease","volume":"15","author":"Friese","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0115","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1128\/JCM.30.11.2881-2886.1992","article-title":"Susceptibility testing of Cryptococcus neoformans: a microdilution technique","volume":"30","author":"Ghannoum","year":"1992","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0120","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1128\/AAC.00048-11","article-title":"Trends in antifungal drug susceptibility of Cryptococcus neoformans obtained through population-based surveillance, South Africa, 2002\u20132003 and 2007\u20132008","volume":"55","author":"Govender","year":"2011","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1086\/313603","article-title":"Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups","volume":"30","author":"Graybill","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0130","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1086\/314606","article-title":"Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group","volume":"179","author":"Hajjeh","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0135","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1086\/507900","article-title":"Free fluconazole for cryptococcal meningitis: Too little of a good thing?","volume":"43","author":"Hamill","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0140","series-title":"Manual of Clinical Microbiology","first-page":"1762","article-title":"Candida, Cryptococcus, and other yeasts of medical importance","author":"Hazen","year":"2007"},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0145","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/dkg312","article-title":"European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria","volume":"52","author":"Kahlmeter","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0150","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0196-4399(04)80015-1","article-title":"Harmonization of antimicrobial breakpoints in Europe \u2014 can it be achieved?","volume":"26","author":"Kahlmeter","year":"2004","journal-title":"Clin. Microbiol. Newsl."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0155","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1128\/JCM.36.12.3653-3656.1998","article-title":"Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987 to 1994","volume":"36","author":"Klepser","year":"1998","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1086\/518583","article-title":"Management of cryptococcal meningitis in AIDS: the need for specific studies in developing countries","volume":"45","author":"Lortholary","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0165","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1097\/QAD.0b013e3280106d6a","article-title":"Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence","volume":"20","author":"McCarthy","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0170","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1128\/JCM.00328-10","article-title":"Anidulafungin potency compared to nine other antifungal agents tested against Candida spp. Cryptococcus spp., and Aspergillus spp: results from the Global SENTRY Antimicrobial Surveillance Program (2008)","volume":"48","author":"Messer","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0175","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1086\/368091","article-title":"The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992\u20132000","volume":"36","author":"Mirza","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0180","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/pmj.77.914.769","article-title":"Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions","volume":"77","author":"Mwaba","year":"2001","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0185","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1086\/649861","article-title":"Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi","volume":"50","author":"Nussbaum","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0190","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/clinids\/19.5.975-a","article-title":"Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis","volume":"19","author":"Paugam","year":"1994","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0195","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1054\/drup.1999.0090","article-title":"Drug resistance in Cryptococcus neoformans","volume":"2","author":"Perfect","year":"1999","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0200","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.diagmicrobio.2011.03.002","article-title":"Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria","volume":"70","author":"Pfaller","year":"2011","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0205","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.drup.2010.09.002","article-title":"Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods","volume":"13","author":"Pfaller","year":"2010","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0210","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1128\/JCM.02161-10","article-title":"Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution","volume":"49","author":"Pfaller","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0215","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/JCM.01590-09","article-title":"Wild-type MIC distributions and epidemiological cutoff values (ECVs) for the echinocandins and Candida spp","volume":"48","author":"Pfaller","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0220","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drup.2011.01.004","article-title":"Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria","volume":"14","author":"Pfaller","year":"2011","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0225","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1128\/JCM.02117-09","article-title":"Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion","volume":"48","author":"Pfaller","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0230","series-title":"Drug resistance in Cryptococcus: epidemiology and molecular mechanisms","author":"Pfaller","year":"2011"},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0235","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1128\/JCM.43.5.2163-2167.2005","article-title":"Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004)","volume":"43","author":"Pfaller","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0240","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1056\/NEJM199503163321102","article-title":"A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group","volume":"332","author":"Powderly","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0245","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJM199203193261203","article-title":"A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group","volume":"326","author":"Powderly","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0250","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1517\/14656566.9.4.551","article-title":"Epidemiology and management of cryptococcal meningitis: developments and challenges","volume":"9","author":"Pukkila-Worley","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0255","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1086\/342384","article-title":"Has antifungal susceptibility testing come of age?","volume":"35","author":"Rex","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0260","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/jac\/dkh361","article-title":"Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002","volume":"54","author":"Sar","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0265","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/jac\/dkm423","article-title":"Potential confusion regarding the term \u2018resistance\u2019 in epidemiological surveys","volume":"61","author":"Simjee","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0270","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/clinids\/23.6.1282","article-title":"Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of < or = 100\/mm3: demonstration of efficacy in a positive, multicenter trial","volume":"23","author":"Singh","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0275","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1086\/592690","article-title":"Cryptococcosis in solid organ transplant recipients: current state of the science","volume":"47","author":"Singh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0280","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1469-0691.2006.01377.x","article-title":"Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values","volume":"12","author":"Turnidge","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0285","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/CMR.00047-06","article-title":"Setting and revising antibacterial susceptibility breakpoints","volume":"20","author":"Turnidge","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0290","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/infdis\/168.2.508","article-title":"Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis","volume":"168","author":"Velez","year":"1993","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0295","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1128\/AAC.41.4.748","article-title":"Fluconazole tolerance in clinical isolates of Cryptococcus neoformans","volume":"41","author":"Venkateswarlu","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0300","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0140-6736(95)92139-7","article-title":"Fulminant cryptococcal infections in HIV-infected patients on oral fluconazole","volume":"346","author":"Viard","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0305","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/clinids\/22.2.322","article-title":"Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing","volume":"22","author":"Witt","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2011.07.007_bb0310","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1046\/j.1439-0507.2002.00765.x","article-title":"In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592)","volume":"45","author":"Yildiran","year":"2002","journal-title":"Mycoses"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889311003026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889311003026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T20:08:05Z","timestamp":1592942885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889311003026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0732889311003026"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2011.07.007","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}